However, inhibition of proteasome occurs at micromolar concentrations (pristimerin at 2.2-3.0 μM inhibited 50% of the proteolytic activity of purified 20S proteasome; pristimerin at 5.0 μM inhibited proteasomal activity by 30%-40% in tumor cells [34]) while the inhibition of Bcr-Abl transcription and inactivation of NF-κB signaling occur in nanomolar concentrations (Figures 3 and 4). The gene discussed is NFKB1; the disease is neoplasm.